ACH 24

Drug Profile

ACH 24

Alternative Names: ACH24

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ache Laboratories
  • Class Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Vitiligo

Most Recent Events

  • 04 Dec 2017 ACH 24 is still at phase I/II development stage for Vitiligo in Brazil (Ache Laboratories pipeline, December 2017)
  • 15 Mar 2016 Brazilian Health Surveillance Agency (ANVISA) requests Ache Laboratories to conduct a phase I trial of ACH 24
  • 15 Mar 2016 Ache Laboratories withdraws a phase III trial for Vitiligo in Brazil (NCT01419964)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top